The Gates Foundation and the Pan American Health Organization are both working on ways to make weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro more accessible in lower-income ...

David Rometo, MD, reflects on the sustainability of incremental weight loss programs and aggressive diets. A weight loss journey with incremental weight loss, healthy eating habits, and physical ...

Have you noticed just how complicated nutrition advice has gotten over the years? "With the rise of influencers on social media, doing the right thing for weight loss and optimal health can seem like ...

David Rometo, MD, weighs various weight loss treatments, their success, and sustainability. Bariatric surgery is more cost-effective and better at helping patients lose and maintain weight than ...

These quick and delicious 30-minute weight-loss meals make putting dinner on the table effortless, even on your busiest nights.

SHANGHAI, Sept 23 (Reuters) - Innovent Biologics' (1801.HK), opens new tab newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals ...

This could really move the needle in the GLP-1 weight loss market. Semaglutide, the active ingredient in Ozempic and Wegovy, is injected into the fatty tissue just under the skin of the stomach, thigh ...

Pfizer PFE-3.43%decrease; red down pointing triangle has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera MTSR 1.16%increase; green up pointing triangle in a deal that gets the ...

She previously revealed that she had experimented with various diets in the past, including an all-liquid plan, but later focused on sustainable changes that better suited her lifestyle. “I’d never do ...

A pill form of the weight loss drug Wegovy was as effective as injections for people with obesity in a clinical trial, the drug's manufacturer said. Novo Nordisk said in its news release that ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines. The drug, known as CT-388, ...

Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs. Pfizer on Monday said ...